May 1, 2025
Research collaboration charts global four-stage evolution of inflammatory bowel disease
Researchers with the 91快色 and the Chinese University of Hong Kong (CUHK) led an international collaboration that found inflammatory bowel disease (IBD) progresses through four predictable epidemiological stages as it spreads globally. Published in Nature, the forecasts a major rise in IBD prevalence in Canada by 2045. Researchers say pinpointing where each region sits on the trajectory gives health-care systems a clear roadmap to anticipate and manage IBD today and in the decades to follow.
鈥淥ur analysis draws on a century worth of historical epidemiologic data. The findings enable health authorities to prepare for IBD鈥檚 growing burden and tailor interventions鈥攚hether clinical, policy driven, or preventive,鈥 says Dr. , MD, professor at U91快色鈥檚 and principal investigator on the study.
Kaplan team prepare for a conference where they will present the findings.
Rachel Braeuer
Data sources
The Global IBD Visualization of Epidemiology Studies in the 21st Century (GIVES-21) consortium collected incidence (new diagnosis made each year) and prevalence (number of people living with the disease) data from more than 500 epidemiological studies conducted across 80 regions over the past century. Using these data, the team developed a machine learning algorithm and predictive modeling to classify countries into four distinct epidemiological stages of IBD evolution: emergence, acceleration in incidence, compounding prevalence, and prevalence equilibrium.
鈥淥ur GIVES-21 consortia is conducting epidemiologic surveillance studies in low- and middle-income countries as the disease is evolving in these regions,鈥 says Dr. Siew Ng, FRCP, PhD, professor at CUHK鈥檚 Faculty of Medicine, and co-principal investigator on the study. 鈥淲e are seeing a paradigm shift of IBD accelerating in region like Asia, and we must build the clinical infrastructure and workforce needed to manage this complex and costly disease.鈥
Dr. Siew Ng, FRCP, PhD, professor at Chinese University of Hong Kong and co-principal investigator on the study.
supplied by Chinese University of Hong Kong
IBD, comprising Crohn鈥檚 disease (CD) and ulcerative colitis (UC), refers to chronic conditions that cause inflammation in the gastrointestinal tract. Onset often occurs in early life with the peak onset between 20 and 40 years of age and can cause lifelong symptoms.
History of IBD
Historically, IBD first emerged in the 19th century in early industrialized Western regions of North America, Europe and Oceania. Over the past two decades, however, IBD appeared in newly industrialized and developing regions across Asia, Latin America and Africa. The combination of rising incidence in newly industrialized countries and steadily increasing prevalence in early industrialized Western countries has made IBD a global health concern.
Based on the findings Kaplan describes the stages of IBD throughout of the world,
鈥淒eveloping regions in Africa, Asia, and Latin America in Stage 1 (emergence) transition to Stage 2 (acceleration in incidence) following economic growth, industrialization, urbanization, and changes in lifestyle and diet,鈥 says Kaplan.
鈥淐ountries in North America, Europe, and Oceania are in Stage 3 (compounding prevalence). They are seeing a growing number of people living with IBD, including an increasing proportion of seniors. These regions face a dual challenge: managing new cases in young adults while also supporting older patients with more complex health needs.鈥
Kaplan adds prevalence of IBD will continue to rise as people live longer with the disease. However, he says as the IBD population ages, the rate of growth is expected to slow鈥攎oving toward Stage 4 (prevalence equilibrium), where new diagnoses are gradually balanced by age-related deaths.
The four epidemiological stages of IBD offer a powerful case study for understanding the global rise of chronic inflammatory diseases shaped by industrialization and modern living.
The first authors on the paper are Dr. Lindsay Hracs, BA 鈥09, MA 鈥11, PhD 鈥21 and Dr. Joseph W. Windsor MA 鈥12, PhD 鈥17, members of the Kaplan lab.
The study was supported by The Leona M. and Harry B. Helmsley Charitable Trust, Canadian Institutes of Health Research, and the International Organization for the study Inflammatory Bowel Disease.
Gilaad Kaplan is a professor in the Department of Medicine and a member of the Snyder Institute for Chronic Diseases, and the O鈥橞rien Institute from Public Health at the Cumming School of Medicine.